Physician Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Physician Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

All India Institute Medical Science, New Delhi

Rifampicin-based salvage therapy not suitable for H. pylori eradication

"In vitro activity of rifampicin has been shown against Helicobacter pylori. It has also been reported that the prevalence of H. pylori is low in patients with tuberculosis treated with rifampicin.

"Clinical trials are required to establish the efficacy of rifampicin as a salvage therapy for eradication of H. pylori. We aimed to evaluate the efficacy of rifampicin-based salvage therapy for eradication of H. pylori in patients with peptic ulcer disease," investigators in India report.

...

• View Other Issues of Physician Law Weekly
  
• View Other NewsRx Publications